Busca avançada
Ano de início
Entree
(Referência obtida automaticamente do Web of Science, por meio da informação sobre o financiamento pela FAPESP e o número do processo correspondente, incluída na publicação pelos autores.)

fficacy of House Dust Mite Sublingual Immunotherapy in Patients with Atopic Dermatitis: A Randomized, Double-Blind, Placebo-Controlled Tria

Texto completo
Autor(es):
Mostrar menos -
Langer, Sarah Sella [1, 2] ; Cardili, Renata Nahas [2] ; Lima Melo, Janaina Michelle [2] ; Leme Ferriani, Mariana Paes [2] ; Moreno, Adriana Santos [2] ; Dias, Marina Mendonca [2] ; Bueno-Filho, Roberto [2] ; Candido Pocente, Renata Helena [2] ; Roxo-Junior, Persio [1] ; Silva, Jorgete [1] ; Pereira Valera, Fabiana Cardoso [3, 4] ; Coelho, Eduardo Barbosa [2] ; Santos Galvao, Clovis Eduardo [5] ; Carmona, Fabio [1] ; Aragon, Davi Casale [1] ; Arruda, Luisa Karla [2]
Número total de Autores: 16
Afiliação do(s) autor(es):
[1] Univ Sao Paulo, Ribeirao Preto Med Sch, Dept Pediat, Ribeirao Preto, SP - Brazil
[2] Univ Sao Paulo, Ribeirao Preto Med Sch, Dept Med, Ribeirao Preto, SP - Brazil
[3] Univ Sao Paulo, Ribeirao Preto Med Sch, Dept Otorhinolaryngol, Ribeirao Preto, SP - Brazil
[4] Univ Sao Paulo, Ribeirao Preto Med Sch Hosp, Clin Res Unit, Ribeirao Preto, SP - Brazil
[5] Univ Sao Paulo, Div Clin Immunol & Allergy, Med Sch Hosp, Sao Paulo, SP - Brazil
Número total de Afiliações: 5
Tipo de documento: Artigo Científico
Fonte: JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY-IN PRACTICE; v. 10, n. 2, p. 539+, FEB 2022.
Citações Web of Science: 1
Resumo

BACKGROUND: Sensitization to house dust mites (HDMs) is frequent in patients with atopic dermatitis. OBJECTIVE: To investigate the efficacy of sublingual immunotherapy (SLIT) with Dermatophagoides pteronyssinus extract in patients with atopic dermatitis sensitized to HDM. METHODS: In this randomized, double-blind, placebo-controlled trial, we enrolled 91 patients 3 years or older, with SCORing Atopic Dermatitis (SCORAD) score greater than or equal to 15 and positive skin test result and/or IgE to D pter-onyssinus. Patients were stratified according to age (<12 and >= 12 years) to receive HDM SLIT or placebo for 18 months. Primary outcome was a greater than or equal to 15-point decrease in SCORAD score. Secondary outcomes were decreases in SCORAD and objective SCORAD, Eczema Area and Severity Index, visual analog scale for symptoms, and pruritus scale scores; Investigator's Global Assessment 0/1; and decrease greater than or equal to 4 points in Dermatology Life Quality Index. Background therapy was maintained. RESULTS: A total of 66 patients completed the study (35 HDM SLIT, 31 placebo). After 18 months, 74.2% and 58% of patients in the HDM SLIT group and the placebo group, respectively, showed greater than or equal to 15-point decrease in SCORAD score (relative risk, 1.28; 95% CI, 0.89-1.83). Significant SCORAD score decreases from baseline of 55.6% and 34.5% in HDM SLIT and placebo groups (mean difference, 20.4; 95% CI, 3.89-37.3), significant objective SCORAD score decreases of 56.8% and 34.9% in HDM SLIT and placebo groups (mean difference, 21.3; 95% CI, 0.66-41.81), and more patients with Investigator's Global Assessment 0/1 in the HDM SLIT group as compared with the placebo group (14 of 35 vs 5 of 31; relative risk, 2.63; 95% CI, 1.09-6.39) were observed at 18 months. CONCLUSIONS: Our results suggest that HDM SLIT may be effective in HDM-sensitized patients as an add-on treatment for atopic dermatitis. (C) 2021 The Authors. Published by Elsevier Inc. on behalf of the American Academy of Allergy, Asthma \& Immunology. (AU)

Processo FAPESP: 19/26678-0 - Dermatite atópica em pacientes brasileiros: aspectos genéticos, resposta imune e imunoterapia em pacientes alérgicos a ácaro
Beneficiário:Luisa Karla de Paula Arruda
Linha de fomento: Auxílio à Pesquisa - Regular